Claim Missing Document
Check
Articles

Found 2 Documents
Search

Clinical Profile of Impaired Hearing in Children with Autism Spectrum Disorder (ASD) at UGM Academic Hospital Lestari, Ade Febrina; Sitaresmi, Mei Neni; Wibowo, Anton Sony; Sari, Shinta Kusumalarna; Ridhayanti, Firda
Academic Hospital Journal Vol 6, No 2 (2024)
Publisher : Rumah Sakit Akademik Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ahj.v6i2.98785

Abstract

Background: Hearing tolerance is impaired in children with Autism Spectrum Disorder (ASD), which can affect social and academic functioning. This study aims to describe the clinical profile of hearing impairments in children with ASD and determine the prevalence of such impairments. Method: A cross-sectional study was conducted at Academic Hospital UGM on pediatric ASD patients aged 18 months to 12 years who underwent hearing exams like BERA (brain-evoked response auditory) and/or audiometry. ASD severity was assessed using the Childhood Autism Rating Scale (CARS) and a questionnaire on demographics and comorbidities, followed by BERA tests. Results:  A total of 41 ASD children were obtained, with 31 children (76%) being boys and an average diagnosis age of 3.3 years (±1.3 SD). Hearing loss was suffered by 4 children (10%) and 37 children (90%) did not experience hearing loss. Sound sensitivity and degree of ASD correlated with head banging (p=0.01), and male gender correlated with hearing loss (P=0.006). CARS score was statistically associated with sound sensitivity (p=0.041) and degree of ASD (<0.001). Conclusion: Children diagnosed with ASD face an increased susceptibility to communication impairments which can be attributed to hearing impairments. This issue warrants particular attention in the context of ASD, highlighting the necessity for thorough screening of hearing capabilities.
Adverse events following immunization (AEFIs) in health workers who receive COVID-19 vaccination at Academic Hospital Universitas Gadjah Mada, Yogyakarta Lestari, Ade Febrina; Sitaresmi, Mei Neni; Haspitaningrum, Anjarsari; Rachmasari, Kusuma Ayu; Wulandari, Ratih; Sari, Shinta Kusumalarna; Ridhayani, Firda
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.6860

Abstract

COVID-19 is a new viral infection that has become a global pandemic, resulting in extremely high mortality and morbidity rates worldwide, including in Indonesia. Vaccination is one of the strategies for preventing COVID-19 infection promoted by the World Health Organization (WHO) to reduce COVID-19 morbidity and mortality. The Indonesian government supports the implementation of vaccination and conducts mass vaccination as a strategy to overcome the pandemic in Indonesia. The high immunization coverage resulted in increased use of vaccines, and events following immunization (AEFI) also increased. Reports on follow-up AEFI are needed as government policy references and information for the public. This study aims to describe the following events after the COVID-19 vaccine immunization and the incidence of the infection post vaccination. The study design was a cross-sectional study using primary and secondary data. The data were analyzed descriptively and statistically using Chi Square method by identifying association between demographic data and AEFI incidence. A total 131 respondents were included. Most respondents experienced AEFI after giving the first (77.1%) or second (71.9%) vaccine with the Sinovac vaccine. However, all reported mild AEFI. Most reported AEFIs were pain (48.8% and 49.6%), hungry (37.4% and 10.0%), and drowsiness (32.1% and 23.7%) after the first and the second vaccine. In conclusion, the prevalence of AEFI in the first and the second dose of inactivated COVID-19 vaccine is higher than that reported in the clinical trial study although the all AEFIs are considered as mild.